血液高凝肺癌患者应用低分子肝素后凝血功能的变化情况

摘要

目的:本试验回顾性研究低分子肝素对血液呈高凝状态的肺癌放化疗患者的抗凝作用.方法:将140例存在血液高凝的肺癌患者根据治疗方案分为放疗试验组、放疗对照组、化疗试验组及化疗对照组,每组35例,其中两试验组在放化疗治疗期间给予低分子肝素抗凝治疗,两对照组仅给予放、化疗.结果:两试验组患者抗凝治疗后,血D-二聚体(D-D)、血浆纤维蛋白原(FIB)及血小板计数(PLT)水平明显下降,而两对照组患者基础治疗后,血D-D、PLT水平明显升高,化疗对照组治疗后FIB水平明显升高,差异有统计学意义(P均<0.05);试验组与对照组相比,静脉血栓(VTE)发生率明显降低,未见明显出血等不良反应.结论:低分子肝素可以有效改善肺癌患者的血液高凝状态,降低VTE发生率,且无明显出血不良事件,具有较高的有效性和安全性.%Objective:To retrospectively observe the anticoagulant effect of low molecular heparin on high blood coagulation state patients with lung cancer during concurrent chemoradiation. Methods:140 hospitalized patients with lung cancer were divided into four groups according to the treatment:Radiation group,radiation control group,chemo-therapy group and chemotherapy control group,35 patients in each group. The two treatment groups were treated with low molecular heparin,however,the control groups were treated with radiation or chemotherapy only. Results:The blood D - D,FIB,PLT level declined obviously of the two treatment group patients after anticoagulation,the control group patients after foundation treatment,blood D - D,PLT level increased significantly,chemotherapy control group after treatment,FIB level increased significantly,the difference was statistically significant(P < 0. 05). Compared with control group,the incidence of venous thrombosis in experimental group was significantly lower,no obvious adverse re-actions such as bleeding. Conclusion:Low molecular heparin can improve high blood coagulation state in the lung cancer patients,and reduce the incidence of VTE,has no obvious bleeding adverse events and has high validity and security.